SCHEMBL980926

SCHEMBL980926

CN1C(=O)CC(Cc2ccccc2)(c2ccc3sccc3c2)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.48
SLC6A4 P31645 5/20 0.48
SLC6A3 Q01959 5/20 0.48
KCNH2 Q12809 3/20 0.48
BACE1 P56817 4/20 0.43
REN P00797 1/20 0.43
CTSD P07339 1/20 0.43
CTNNB1 P35222 1/20 0.35
WNT3A P56704 1/20 0.35
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
CYP2D6 P10635 2/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
CYP2A6 P11509 1/20 0.33
CYP19A1 P11511 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984613 0.86 REN (0.51) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL983004 0.74 REN (0.48) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL983369 0.72 MEN1 (0.39) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL981018 0.70 SLC6A4 (0.61) SLC6A2SLC6A4SLC6A3KCNH2BACE1
Hydrochloric Acid SCHEMBL984582 0.70 SLC6A2 (0.60) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL7536148 0.68 CYP19A1 (0.35) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL7547569 0.68 REN (0.43) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL7544329 0.68 REN (0.48) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL8195141 0.67 BACE1 (0.34) SLC6A2SLC6A4SLC6A3KCNH2BACE1
SCHEMBL980880 0.66 SLC6A2 (0.61) SLC6A2SLC6A4SLC6A3KCNH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 SLC6A2 6/4885SLC6A4 8/4885SLC6A3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.